You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The data also point to viral load reductions regardless of disease genotype, extent of patient liver fibrosis, or failure with other treatments.
The company also disclosed that it intends to continue working on its non-HBV RNAi drugs that have entered human testing, but was less clear about earlier-stage ones.
The news marks a key milestone for Tekmira, which announced earlier this month that it would merge with OnCore Biopharma to become an HBV-focused drug developer.
The news marks the latest setback for the company, which came under fire late last year over disappointing clinical results on the drug.
Following the transaction, hepatitis B will become Tekmira's top priority, although the company said it will continue work on its other RNAi programs.
The real-time PCR assay is designed to detect and identify HIV, hepatitis B virus, and hepatitis C virus in donations of human whole blood and blood components.
The studies will test Arrowhead's drug in combination with one of two direct-acting antiviral therapies.
The new claims allow for pre-transplantation testing of organ and tissue donations for HIV, hepatitis B virus, hepatitis C virus, and West Nile virus.
Roche today said that its Cobas HIV-1 and HCV next-generation viral load monitoring assays have received CE marking.
Officials said the firm remains confident in its HBV drug despite investors' negative reaction to Phase IIa data.
A new analysis suggests warming, not the arrival of humans, led to the extinction of the woolly rhinoceros thousands of years ago, the Economist reports.
Chinese health officials uncovered SARS-CoV-2 viral RNA on imported frozen food, but the New York Times reports catching COVID-19 that way would be unlikely.
The UK has ordered 60 million coronavirus vaccine doses from Novavax and 30 million doses from Janssen, according to the Guardian.
In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.